GSK clinches $170M malaria vaccine supply deal after 3 decades of research

While GSK’s ego may have been bruised after an initial failure to develop a COVID-19 shot, its bread-and-butter immunization business is making strides elsewhere. Look no further than malaria, where the world’s biggest buyer of vaccines has agreed to purchase supplies of the company’s Mosquirix.